VEGFA and neoplasm: In a study of the phenotypic, physiologic, and molecular tumor response to bevacizumab, a recombinant humanized monoclonal anti-VEGF antibody, Keunen et al. found that vascular remodeling and the creation of a more hypoxic tumor microenvironment paradoxically resulted in a more invasive, glycolysis-dependent tumor phenotype [93].